Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Chan, Arlene; Moy, Beverly; Mansi, Janine; Ejlertsen, Bent; Holmes, Frankie; Chia, Stephen; Iwata, Hiroji; Gnant, Michael; Loibl, Sibylle; Barrios, Carlos; Somali, Isil; Smichkoska, Snezhana; Martinez, Noelia; Alonso, Mirta; Link, John; Mayer, Ingrid; Cold, Soren; Murillo, Serafin; Senecal, Francis; Inoue, Kenichi; Ruiz-Borrego, Manuel; Hui, Rina; Denduluri, Neelima; Patt, Debra; Rugo, Hope; Johnston, Stephen; Bryce, Richard; Zhang, Bo; Xu, Feng; Wong, Alvin; Martin, Miguel

doi:10.1016/j.clbc.2020.09.014

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Chan A., Moy B., Mansi J., Ejlertsen B., Holmes F. A., Chia S., ...More

CLINICAL BREAST CANCER, vol.21, no.1, pp.80-98, 2021 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 21 Issue: 1
Publication Date: 2021
Doi Number: 10.1016/j.clbc.2020.09.014
Journal Name: CLINICAL BREAST CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Page Numbers: pp.80-98
Keywords: Adjuvant therapy, Disease-free survival, Distant disease-free survival, Neoadjuvant therapy, Overall survival
Open Archive Collection: AVESIS Open Access Collection
Dokuz Eylül University Affiliated: Yes

Abstract

In the patient population with early-stage human epidermal growth factor receptor 2-positive/hormone receptor-positive breast cancer who initiate neratinib within 1 year of trastuzumab-based therapy, the absolute 5-year invasive disease-free survival benefit versus placebo is 5.1%, and absolute 8-year overall survival benefit is 2.1%. Among those with residual disease after neoadjuvant therapy (non-pathologic complete response), absolute gains with neratinib are 7.4% and 9.1%, respectively.